Corcept Therapeutics IncCORT
Price$114.03Intrinsic value$17.0285% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $830.8M+23.1% YoYTTM through 30 Jun 2026
Net Income $55.2M-60.9% YoYTTM through 30 Jun 2026
Free Cash Flow $106.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin98.3%
EBITDA Margin1.0%
Operating Margin-30.1%
Net Margin6.6%

Returns

-5.0%ROE
6.2%ROA
9.3%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.86x
Net Debt-$515.4Mnet cash position
Cash & Equivalents$111M

Quality Metrics

Altman Z-Score44.04
Piotroski F-Score5 / 9
FCF Margin12.9%
Rule of 4050.9
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $761.4M
Diluted EPS$0.45TTM
'19'20'21'22'23'24'25
FY2025: $0.82

Dividend

No dividend

Capital Allocation

R&D Spend$253.9M
Capex Intensity0.3%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.